• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对 SARS-CoV-2 主蛋白酶抑制剂的生化筛选。

Biochemical screening for SARS-CoV-2 main protease inhibitors.

机构信息

Department of Science and Technology, Federal University of São Paulo, São José dos Campos, Brazil.

Department of Physics, University of South Florida, Tampa, FL, United States of America.

出版信息

PLoS One. 2020 Oct 6;15(10):e0240079. doi: 10.1371/journal.pone.0240079. eCollection 2020.

DOI:10.1371/journal.pone.0240079
PMID:33022015
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7537881/
Abstract

The Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) pandemic represents a global challenge. SARS-CoV-2's ability to replicate in host cells relies on the action of its non-structural proteins, like its main protease (Mpro). This cysteine protease acts by processing the viruses' precursor polyproteins. As proteases, together with polymerases, are main targets of antiviral drug design, we here have performed biochemical high throughput screening (HTS) with recombinantly expressed SARS-CoV-2 Mpro. A fluorescent assay was used to identify inhibitors in a compound library containing known drugs, bioactive molecules and natural products. These screens led to the identification of 13 inhibitors with IC50 values ranging from 0.2 μM to 23 μM. The screens confirmed several known SARS-CoV Mpro inhibitors as inhibitors of SARS-CoV-2 Mpro, such as the organo-mercuric compounds thimerosal and phenylmercuric acetate. Benzophenone derivatives could also be identified among the most potent screening hits. Additionally, Evans blue, a sulfonic acid-containing dye, could be identified as an Mpro inhibitor. The obtained compounds could be of interest as lead compounds for the development of future SARS-CoV-2 drugs.

摘要

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)大流行是全球性挑战。SARS-CoV-2 在宿主细胞中复制的能力依赖于其非结构蛋白的作用,例如其主要蛋白酶(Mpro)。这种半胱氨酸蛋白酶通过处理病毒的前体多蛋白发挥作用。由于蛋白酶与聚合酶一样是抗病毒药物设计的主要靶标,我们在此使用重组表达的 SARS-CoV-2 Mpro 进行了生化高通量筛选(HTS)。荧光测定法用于鉴定包含已知药物、生物活性分子和天然产物的化合物库中的抑制剂。这些筛选确定了 13 种抑制剂,其 IC50 值范围为 0.2 μM 至 23 μM。筛选证实了几种已知的 SARS-CoV Mpro 抑制剂也是 SARS-CoV-2 Mpro 的抑制剂,例如有机汞化合物硫柳汞和苯汞乙酸盐。苯甲酮衍生物也可以在最有效的筛选命中物中被识别出来。此外,埃文斯蓝,一种含磺酸的染料,也可以被鉴定为 Mpro 抑制剂。获得的化合物可能作为未来开发 SARS-CoV-2 药物的先导化合物具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99eb/7537881/33d4b56cc97b/pone.0240079.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99eb/7537881/e4ed7bc12f26/pone.0240079.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99eb/7537881/ba5829fa2b53/pone.0240079.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99eb/7537881/5dd482d4368c/pone.0240079.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99eb/7537881/fb0d1a3ea63c/pone.0240079.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99eb/7537881/33d4b56cc97b/pone.0240079.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99eb/7537881/e4ed7bc12f26/pone.0240079.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99eb/7537881/ba5829fa2b53/pone.0240079.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99eb/7537881/5dd482d4368c/pone.0240079.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99eb/7537881/fb0d1a3ea63c/pone.0240079.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99eb/7537881/33d4b56cc97b/pone.0240079.g005.jpg

相似文献

1
Biochemical screening for SARS-CoV-2 main protease inhibitors.针对 SARS-CoV-2 主蛋白酶抑制剂的生化筛选。
PLoS One. 2020 Oct 6;15(10):e0240079. doi: 10.1371/journal.pone.0240079. eCollection 2020.
2
Optimization Rules for SARS-CoV-2 M Antivirals: Ensemble Docking and Exploration of the Coronavirus Protease Active Site.SARS-CoV-2 M 抗病毒药物的优化规则:冠状病毒蛋白酶活性位点的整体对接和探索。
Viruses. 2020 Aug 26;12(9):942. doi: 10.3390/v12090942.
3
Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.基于配体/基于结构的虚拟筛选、分子动力学模拟和结合能计算发现 SARS-CoV-2 主要蛋白酶的有效抑制剂。
Phys Chem Chem Phys. 2020 Oct 21;22(40):23099-23106. doi: 10.1039/d0cp04326e.
4
Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.基于结构的虚拟筛选和小分子抑制猫冠状病毒 3CL 蛋白酶的体外检测,作为冠状病毒的替代平台。
Antiviral Res. 2020 Oct;182:104927. doi: 10.1016/j.antiviral.2020.104927. Epub 2020 Sep 7.
5
Structure-based lead optimization of herbal medicine rutin for inhibiting SARS-CoV-2's main protease.基于结构的中草药芦丁抑制 SARS-CoV-2 主蛋白酶的先导优化。
Phys Chem Chem Phys. 2020 Nov 21;22(43):25335-25343. doi: 10.1039/d0cp03867a. Epub 2020 Nov 3.
6
Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL Reporter Assay.基于荧光的高通量 SARS-CoV-2 3CL 报告酶测定法的建立。
J Virol. 2020 Oct 27;94(22). doi: 10.1128/JVI.01265-20.
7
In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.新型 SARS-CoV-2 病毒主要蛋白酶的批准蛋白酶抑制剂的有效性的计算机评估。
Molecules. 2020 May 29;25(11):2529. doi: 10.3390/molecules25112529.
8
Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening.SARS-CoV-2 3CLpro 的结构稳定性和通过实验筛选鉴定槲皮素为抑制剂。
Int J Biol Macromol. 2020 Dec 1;164:1693-1703. doi: 10.1016/j.ijbiomac.2020.07.235. Epub 2020 Aug 1.
9
Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design.结构与进化分析表明,SARS-CoV-2 Mpro 是小分子抑制剂设计极具挑战性的靶标。
Int J Mol Sci. 2020 Apr 28;21(9):3099. doi: 10.3390/ijms21093099.
10
Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.靶向冠状病毒主蛋白酶的二聚化:一种有潜力的广谱治疗策略。
ACS Comb Sci. 2020 Jun 8;22(6):297-305. doi: 10.1021/acscombsci.0c00058. Epub 2020 May 27.

引用本文的文献

1
Nasal Spray Disinfectant for Respiratory Infections Based on Functionalized Silver Nanoparticles: A Physicochemical and Docking Approach.基于功能化银纳米颗粒的呼吸道感染鼻腔喷雾消毒剂:物理化学与对接方法
Nanomaterials (Basel). 2025 Mar 31;15(7):533. doi: 10.3390/nano15070533.
2
Remedying SARS-CoV-2 through nature: a review highlighting the potentiality of herbs, trees, mushrooms, and endophytic microorganisms in controlling Coronavirus.利用自然疗法对抗新冠病毒:一篇综述,强调草药、树木、蘑菇和内生微生物在控制冠状病毒方面的潜力。
Planta. 2025 Mar 16;261(4):89. doi: 10.1007/s00425-025-04647-8.
3
An isothermal calorimetry assay for determining steady state kinetic and Ensitrelvir inhibition parameters for SARS-CoV-2 3CL-protease.

本文引用的文献

1
Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?非传统免疫调节剂能否缓解 COVID-19 症状和严重程度?
mSphere. 2020 May 13;5(3):e00288-20. doi: 10.1128/mSphere.00288-20.
2
COVID-19 cytokine storm: the interplay between inflammation and coagulation.新型冠状病毒肺炎细胞因子风暴:炎症与凝血之间的相互作用
Lancet Respir Med. 2020 Jun;8(6):e46-e47. doi: 10.1016/S2213-2600(20)30216-2. Epub 2020 Apr 27.
3
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.
一种用于测定新型冠状病毒 3CL 蛋白酶稳态动力学和恩昔替尼抑制参数的等温滴定量热法检测。
Sci Rep. 2024 Dec 31;14(1):32175. doi: 10.1038/s41598-024-81990-y.
4
Taming the storm: potential anti-inflammatory compounds targeting SARS-CoV-2 MPro.驯服风暴:靶向 SARS-CoV-2 MPro 的潜在抗炎化合物。
Inflammopharmacology. 2024 Oct;32(5):3007-3035. doi: 10.1007/s10787-024-01525-9. Epub 2024 Jul 24.
5
Yeast-Based Screening of Anti-Viral Molecules.基于酵母的抗病毒分子筛选
Microorganisms. 2024 Mar 14;12(3):578. doi: 10.3390/microorganisms12030578.
6
Antiviral Effects of Secondary Metabolites from Leaves against the Pseudotyped Virus of SARS-CoV-2 Omicron.叶片次生代谢产物对严重急性呼吸综合征冠状病毒2奥密克戎变异株假型病毒的抗病毒作用
Plants (Basel). 2023 Nov 23;12(23):3942. doi: 10.3390/plants12233942.
7
Porphyrin-derived carbon dots for an enhanced antiviral activity targeting the CTD of SARS-CoV-2 nucleocapsid.用于增强针对新冠病毒核衣壳CTD的抗病毒活性的卟啉衍生碳点
J Genet Eng Biotechnol. 2023 Oct 6;21(1):93. doi: 10.1186/s43141-023-00548-z.
8
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review.SARS-CoV 和 SARS-CoV-2 主要蛋白酶的结构与功能及其抑制作用:全面综述。
Eur J Med Chem. 2023 Nov 15;260:115772. doi: 10.1016/j.ejmech.2023.115772. Epub 2023 Aug 28.
9
A Prototype Assay Multiplexing SARS-CoV-2 3CL-Protease and Angiotensin-Converting Enzyme 2 for Saliva-Based Diagnostics in COVID-19.一种用于基于唾液的 COVID-19 诊断的 SARS-CoV-2 3CL-蛋白酶和血管紧张素转化酶 2 的原型检测多重分析。
Biosensors (Basel). 2023 Jun 27;13(7):682. doi: 10.3390/bios13070682.
10
Silver N-heterocyclic carbene complexes are potent uncompetitive inhibitors of the papain-like protease with antiviral activity against SARS-CoV-2.银氮杂环卡宾配合物是木瓜蛋白酶样蛋白酶的有效非竞争性抑制剂,对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)具有抗病毒活性。
RSC Med Chem. 2023 May 16;14(7):1260-1271. doi: 10.1039/d3md00067b. eCollection 2023 Jul 20.
基于结构的针对 SARS-CoV-2 主蛋白酶的抗病毒药物候选物的设计。
Science. 2020 Jun 19;368(6497):1331-1335. doi: 10.1126/science.abb4489. Epub 2020 Apr 22.
4
A Review of SARS-CoV-2 and the Ongoing Clinical Trials.SARS-CoV-2 综述及正在进行的临床试验。
Int J Mol Sci. 2020 Apr 10;21(7):2657. doi: 10.3390/ijms21072657.
5
Structure of M from SARS-CoV-2 and discovery of its inhibitors.SARS-CoV-2 M 结构与抑制剂的发现
Nature. 2020 Jun;582(7811):289-293. doi: 10.1038/s41586-020-2223-y. Epub 2020 Apr 9.
6
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.SARS-CoV-2 主蛋白酶的晶体结构为设计改良的 α-酮酰胺抑制剂提供了基础。
Science. 2020 Apr 24;368(6489):409-412. doi: 10.1126/science.abb3405. Epub 2020 Mar 20.
7
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素:一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
8
A new coronavirus associated with human respiratory disease in China.一种在中国与人类呼吸道疾病相关的新型冠状病毒。
Nature. 2020 Mar;579(7798):265-269. doi: 10.1038/s41586-020-2008-3. Epub 2020 Feb 3.
9
A pneumonia outbreak associated with a new coronavirus of probable bat origin.一种新型冠状病毒引发的肺炎疫情,该病毒可能来源于蝙蝠。
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.
10
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.新冠病毒的基因组特征和流行病学:对病毒起源和受体结合的影响。
Lancet. 2020 Feb 22;395(10224):565-574. doi: 10.1016/S0140-6736(20)30251-8. Epub 2020 Jan 30.